Stockscreener 앱 받기
64.71
3.11%
1.31
전일 마감가:
$63.40
열려 있는:
$65.49
하루 거래량:
33,767
Relative Volume:
0.18
시가총액:
$432.40M
수익:
-
순이익/손실:
$-7.12M
주가수익비율:
-28.13
EPS:
-2.3
순현금흐름:
$-6.82M
1주 성능:
-0.97%
1개월 성능:
-13.35%
6개월 성능:
+61.65%
1년 성능:
+167.25%
1일 변동 폭
$64.27
$66.64
1주일 범위
$56.15
$66.64
52주 변동 폭
$24.00
$105.00
Monopar Therapeutics Inc Stock (MNPR) Company Profile
명칭
Monopar Therapeutics Inc
전화
(847) 388-0349
주소
1000 SKOKIE BLVD SUITE 350, WILMETTE
MNPR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MNPR
Monopar Therapeutics Inc
|
64.70 | 423.68M | 0 | -7.12M | -6.82M | -2.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.39 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
808.90 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
408.56 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
812.83 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
176.28 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Monopar Therapeutics Inc Stock (MNPR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-14 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2025-11-10 | 개시 | Leerink Partners | Outperform |
| 2025-10-13 | 개시 | Barclays | Overweight |
| 2025-09-09 | 개시 | BTIG Research | Buy |
| 2025-09-03 | 개시 | Oppenheimer | Outperform |
| 2025-09-03 | 개시 | Raymond James | Strong Buy |
| 2025-08-26 | 재개 | H.C. Wainwright | Buy |
| 2025-07-07 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-06-23 | 개시 | Chardan Capital Markets | Buy |
| 2025-03-19 | 재개 | Piper Sandler | Overweight |
| 2025-01-10 | 개시 | Piper Sandler | Overweight |
| 2024-10-11 | 개시 | Rodman & Renshaw | Buy |
| 2021-01-28 | 개시 | ROTH Capital | Buy |
모두보기
Monopar Therapeutics Inc 주식(MNPR)의 최신 뉴스
Morgan Stanley initiates Monopar Therapeutics stock with Overweight rating By Investing.com - Investing.com Canada
Monopar Therapeutics Inc. (NASDAQ:MNPR) Receives Average Rating of “Buy” from Brokerages - Defense World
How risky is Monopar Therapeutics Inc. stock nowWeekly Investment Recap & Free Community Consensus Stock Picks - ulpravda.ru
Will Monopar Therapeutics Inc. stock return to pre crisis levelsJuly 2025 News Drivers & Fast Moving Stock Watchlists - ulpravda.ru
Can Monopar Therapeutics Inc. stock hit record highs again2025 Macro Impact & Weekly Return Optimization Alerts - ulpravda.ru
Published on: 2026-01-09 02:04:15 - ulpravda.ru
Will Monopar Therapeutics Inc. stock keep outperforming rivalsEntry Point & Low Risk Investment Opportunities - ulpravda.ru
Published on: 2026-01-08 22:24:28 - ulpravda.ru
Trading the Move, Not the Narrative: (MNPR) Edition - Stock Traders Daily
EPS Watch: What dividend safety score for Monopar Therapeutics Inc. stock2025 Momentum Check & Verified Swing Trading Watchlists - moha.gov.vn
Monopar Therapeutics announces pricing of $135M offering - MSN
Aug Gainers: Why Monopar Therapeutics Inc stock appeals to analystsProfit Target & Fast Momentum Stock Entry Tips - moha.gov.vn
Hedge Fund Moves: Is Monopar Therapeutics Inc stock a buy for dividend growthSwing Trade & Technical Entry and Exit Alerts - moha.gov.vn
Top Executive Makes Bold Insider Move at Monopar Therapeutics - TipRanks
Insider Buying: Quan Vu Acquires Shares of Monopar Therapeutics Inc (MNPR) - GuruFocus
Monopar Therapeutics (NASDAQ:MNPR) CFO Purchases 1,500 Shares - MarketBeat
Monopar therapeutics CFO Vu Quan Anh buys $104925 in shares By Investing.com - Investing.com Canada
Monopar Therapeutics (NASDAQ:MNPR) Sharpens Focus on Molecular Targeting - Kalkine Media
Wall Street Analysts Predict a 51.26% Upside in Monopar Therapeutics (MNPR): Here's What You Should Know - MSN
Monopar Therapeutics Inc. (NASDAQ:MNPR) Short Interest Update - MarketBeat
Responsive Playbooks and the MNPR Inflection - Stock Traders Daily
What Awaits These 4 Biotech Stocks That More Than Doubled in 2025 - Zacks Investment Research
Independent Director Arthur Klausner Sold A Bunch Of Shares In Monopar Therapeutics - simplywall.st
What dividend safety score for Monopar Therapeutics Inc. stockStop Loss & AI Powered Buy and Sell Recommendations - Улправда
Major Insider Move Shakes Up Investor Watch on Monopar Therapeutics - TipRanks
Is Monopar Therapeutics Inc. stock a safe haven assetJuly 2025 Summary & Accurate Intraday Trading Signals - Улправда
Insider Sell: Arthur Klausner Sells Shares of Monopar Therapeuti - GuruFocus
Dir Klausner Files To Sell 5,121 Of Monopar Therapeutics Inc [MNPR] - TradingView — Track All Markets
Monopar Therapeutics Director Sells Over 5,000 Shares - TradingView — Track All Markets
Monopar Therapeutics Insider Sold Shares Worth $343,889, According to a Recent SEC Filing - marketscreener.com
Dir Klausner Sells 5,121 ($343.9K) Of Monopar Therapeutics Inc [MNPR] - TradingView — Track All Markets
Monopar Therapeutics (FRA:1IY0) EV-to-OCF : -25.58 (As of Dec. 19, 2025) - GuruFocus
Will Monopar Therapeutics Inc. stock gain from strong economyWeekly Stock Report & Weekly High Conviction Ideas - DonanımHaber
Why retail investors favor Monopar Therapeutics Inc. stock2025 Momentum Check & Community Shared Stock Ideas - DonanımHaber
Why Monopar Therapeutics Inc. stock appeals to analystsJuly 2025 PreEarnings & High Return Stock Watch Alerts - DonanımHaber
Is Monopar Therapeutics Inc. (1IY0) stock a good hedge against inflation2025 Retail Activity & Technical Buy Zone Confirmation - DonanımHaber
How cyclical is Monopar Therapeutics Inc. (1IY0) stock compared to rivalsGold Moves & High Accuracy Swing Trade Signals - Улправда
Treasury Yields: How cyclical is Monopar Therapeutics Inc. (1IY0) stock compared to rivalsInsider Buying & Community Verified Trade Signals - Улправда
Monopar Therapeutics (MNPR) director details 43,499-share distribution in Form 4 - Stock Titan
Monopar Therapeutics (MNPR) director receives 7,710 common shares via distribution - Stock Titan
(MNPR) Movement Within Algorithmic Entry Frameworks - news.stocktradersdaily.com
Monopar Therapeutics (NASDAQ:MNPR) Rating Increased to Hold at Wall Street Zen - Defense World
Monopar Therapeutics Inc. (NASDAQ:MNPR) Given Average Recommendation of "Buy" by Brokerages - MarketBeat
Monopar Therapeutics Inc. (NASDAQ:MNPR) Given Average Recommendation of “Buy” by Brokerages - Defense World
Monopar Therapeutics (NASDAQ:MNPR) Upgraded at Wall Street Zen - MarketBeat
Analysts’ Top Healthcare Picks: Aardvark Therapeutics, Inc. (AARD), Eli Lilly & Co (LLY) - The Globe and Mail
Aug Catalysts: How interest rate cuts could boost Monopar Therapeutics Inc stockGap Up & High Accuracy Trade Alerts - moha.gov.vn
Monopar Therapeutics (NASDAQ:MNPR) Shares Up 6.3%Should You Buy? - MarketBeat
Monopar Therapeutics (NASDAQ:MNPR) Downgraded to Sell Rating by Wall Street Zen - MarketBeat
Will Monopar Therapeutics Inc. stock benefit from commodity prices2025 Winners & Losers & Safe Swing Trade Setup Alerts - Newser
Will Monopar Therapeutics Inc. (1IY0) stock rise with strong economyShare Buyback & Free Weekly Watchlist of Top Performers - Newser
Monopar Therapeutics Inc (MNPR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.10%
자본화:
|
볼륨(24시간):